News & Events about Fulcrum Therapeutics Inc.
Fulcrum Therapeutics (NASDAQ:FULC Get Rating) had its price target trimmed by Oppenheimer from $30.00 to $26.00 in a report issued on Thursday, The Fly reports. FULC has been the subject of a number of other research reports. Morgan Stanley increased their target price on Fulcrum Therapeutics from $...
CAMBRIDGE, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the pricing of an underwritten public offering of 9,615,384 ...
Fulcrum Therapeutics, Inc. (NASDAQ:FULC Get Rating) major shareholder Ra Capital Management, L.P. purchased 180,703 shares of the businesss stock in a transaction dated Wednesday, January 4th. The stock was bought at an average cost of $7.28 per share, with a total value of $1,315,517...
Fulcrum Therapeutics, Inc. (NASDAQ:FULC Get Rating) major shareholder Ra Capital Management, L.P. purchased 1,341,420 shares of the companys stock in a transaction dated Friday, December 16th. The stock was bought at an average cost of $5.42 per share, for a total transaction of $7,270,496.40. ...